Harmony Biosciences Holdings, Inc. HRMY 深 沪
已收盘 05-08 16:00:00 美东时间
30.99
-0.430
-1.37%
华盛通- 最 高32.30
- 今 开31.91
- 成交量 75.08万股
- 最 低 30.96
- 昨 收 31.42
- 总市值 17.93亿
- 52周最高 40.87
- 市盈率 静 11.43
- 换手率 1.30%
- 52周最低 25.52
- 委 比 14.29%
- 总股本 5786.74万
- 历史最高 62.085
- 量 比 0.79
- 振 幅 4.26%
- 历史最低 18.6112
- 每 手 1
- 风险率 3.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $29
Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $25 to $29.
05-09 01:07
财报速睇 | Harmony Biosciences Holdings, Inc. 2026财年Q1营收2.15亿美元，同比增长16.6%；归母净利润0.32亿美元，同比下滑28.7%
华盛资讯5月7日讯，Harmony Biosciences Holdings, Inc.公布2026财年Q1业绩，公司Q1营收2.15亿美元，同比增长16.6%，归母净利润0.32亿美元，同比下滑28.7%。
05-07 21:47
财报速睇 | Harmony Biosciences Holdings, Inc. 2026财年Q1营收2.15亿美元，同比增长16.6%；归母净利润0.32亿美元，同比下滑28.7%
华盛资讯5月7日讯，Harmony Biosciences Holdings, Inc.公布2026财年Q1业绩，公司Q1营收2.15亿美元，同比增长16.6%，归母净利润0.32亿美元，同比下滑28.7%。
05-07 20:31
Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est
Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.020 billion estimate.
05-07 19:43
Harmony Biosciences Q1 Adj. EPS $0.55 Misses $0.69 Estimate, Sales $215.400M Miss $225.227M Estimate
Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.69 by 20.29 percent. This is a 46.6 percent decrease over earnings of $1.03 per share
05-07 19:38
Harmony Bio spikes after new Wakix patent litigation
Shares of Harmony Biosciences (HRMY) climbed on Tuesday after Mizuho issued bullish remarks on the stock, citing a new patent litigation filed by the company to fight generics targeting its sleep diso...
04-22 01:23
Harmony Biosciences Appoints Glenn Reicin CFO, Effective Immediately; Co. Reiterates 2026 Net Product Revenue Outlook Range $1B - $1.04B
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial
04-14 20:13
Harmony Biosciences announces annual shareholder meeting via webcast
Harmony Biosciences announces annual shareholder meeting via webcast Harmony Biosciences set annual stockholder meeting for May 14, 2026, to be held virtually. Ballot includes election of four Class III directors to serve through 2029, including nominees Geno Germano, Troy Ignelzi, Ron Philip, Andre
04-03 20:02
Harmony Biosciences Announces The Appointment Of Peter Anastasiou As Chief Operating Officer
Appointments support Harmony's next phase of growth and long‑term value creationHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates
04-02 20:11
Harmony Biosciences to Participate in Upcoming Investor Conferences in Miami
Harmony Biosciences to Participate in Upcoming Investor Conferences in Miami Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) said its management team will attend upcoming investor conferences in Miami, Florida: the Leerink Partners Global Healthcare Conference and the UBS Biotech Summit on March 9
03-04 21:05
